A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Clinical trial NCT05630755 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05630755
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-17
- Primary completion
- 2024-10-25
- Enrollment
- 514
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.